Atlas Trials

Kura Oncology, Inc.

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Kura Oncology, Inc.

RecordFirmDate
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (NCT07007312)Kura Oncology, Inc.2025-09-26
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (NCT06655246)Kura Oncology, Inc.2025-03-27
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788)Kura Oncology, Inc.2024-02-22
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (NCT06026410)Kura Oncology, Inc.2023-10-18
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML (NCT05735184)Kura Oncology, Inc.2023-07-18
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer (NCT05693090)Kura Oncology, Inc.2023-02-01
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (NCT04997902)Kura Oncology, Inc.2021-12-07
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies (NCT04865159)Kura Oncology, Inc.2021-05-06
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336)Kura Oncology, Inc.2019-09-12
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (NCT03719690)Kura Oncology, Inc.2019-03-15

Track Kura Oncology, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.